Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.

Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's research and development of SQ-22031 eye drops has completed the enrollment of the first subject in a Phase II clinical trial to evaluate the effectiveness and safety of SQ-22031 eye drops in the treatment of moderate to severe dry eye in a multi-center, randomized, double-blind, placebo-controlled study. According to the announcement, the Phase II study of SQ-22031 eye drops for dry eye is a multi-center, randomized, double-blind, placebo-controlled clinical study. The aim is to evaluate the effectiveness and safety of SQ-22031 eye drops in patients with moderate to severe dry eye, and to analyze its immunogenicity and its impact on changes in corneal nerve density.